| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
803.49(B) |
| Last
Volume: |
10,848,221 |
Avg
Vol: |
3,295,136 |
| 52
Week Range: |
$720.91 - $960.02 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 412 |
| Guru Rank Value : 5.2 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
881,000 |
881,900 |
2,880,059 |
6,056,565 |
| Total Sell Value |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
11 |
39 |
86 |
| End Date |
2025-01-19 |
2024-10-18 |
2024-04-19 |
2023-04-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Greene Gabrielle E |
Director |
– • – |
2025-03-17 |
4 |
A |
$824.76 |
$4,958 |
D/D |
6 |
2,556 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2025-03-17 |
4 |
A |
$824.76 |
$11,750 |
D/D |
14 |
54,833 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-03-17 |
4 |
A |
$824.76 |
$9,917 |
D/D |
12 |
1,919 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2025-03-17 |
4 |
A |
$824.76 |
$9,917 |
D/D |
12 |
72,827 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-03-17 |
4 |
A |
$824.76 |
$14,833 |
D/D |
18 |
16,276 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2025-03-13 |
4 |
AS |
$818.24 |
$818,240 |
D/D |
(1,000) |
5,840 |
|
-9% |
|
| Lilly Endowment Inc |
|
– – • |
2025-03-03 |
4 |
S |
$922.42 |
$204,326,151 |
D/D |
(220,000) |
96,016,978 |
|
10% |
|
| Dozier Eric |
EVP, Chief People Officer |
• – – |
2025-03-01 |
4 |
D |
$920.63 |
$981,587 |
D/D |
(1,066) |
9,839 |
|
- |
|
| Dozier Eric |
EVP, Chief People Officer |
• – – |
2025-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,403 |
10,905 |
|
- |
|
| Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
• – – |
2025-03-01 |
4 |
D |
$920.63 |
$1,160,293 |
D/D |
(1,260) |
39,748 |
|
- |
|
| Hernandez Edgardo |
EVP & Pres., Mfg. Operations |
• – – |
2025-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,837 |
41,009 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-02-25 |
4 |
S |
$900.50 |
$203,190,794 |
D/D |
(225,000) |
96,236,978 |
|
7% |
|
| Lilly Endowment Inc |
|
– – • |
2025-02-24 |
4 |
S |
$877.31 |
$1,648,756,040 |
D/D |
(60,432) |
96,461,978 |
|
5% |
|
| Lilly Endowment Inc |
|
– – • |
2025-02-21 |
4 |
S |
$877.31 |
$87,786,505 |
D/D |
(99,452) |
96,522,410 |
|
4% |
|
| Lilly Endowment Inc |
|
– – • |
2025-02-20 |
4 |
S |
$877.44 |
$12,893,353 |
D/D |
(14,685) |
96,621,862 |
|
4% |
|
| Dozier Eric |
EVP, Chief People Officer |
• – – |
2025-02-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
460 |
8,502 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-02-19 |
4 |
S |
$877.37 |
$8,771,285 |
D/D |
(9,985) |
96,636,547 |
|
3% |
|
| Greene Gabrielle E |
Director |
– • – |
2025-02-18 |
4 |
A |
$857.20 |
$4,958 |
D/D |
6 |
2,545 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2025-02-18 |
4 |
A |
$857.20 |
$11,750 |
D/D |
14 |
54,719 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2025-02-18 |
4 |
A |
$857.20 |
$9,917 |
D/D |
12 |
1,904 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2025-02-18 |
4 |
A |
$857.20 |
$9,917 |
D/D |
12 |
72,683 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2025-02-18 |
4 |
A |
$857.20 |
$14,833 |
D/D |
17 |
16,229 |
|
- |
|
| Lilly Endowment Inc |
|
– – • |
2025-02-13 |
4 |
S |
$877.47 |
$31,175,396 |
D/D |
(35,446) |
96,646,532 |
|
4% |
|
| Van Naarden Jacob |
EVP & Pres., Lilly Oncology |
• – – |
2025-02-10 |
4 |
A |
$868.88 |
$5,303,491 |
D/D |
6,104 |
19,562 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2025-02-10 |
4 |
A |
$868.88 |
$1,181,381 |
D/D |
1,360 |
6,840 |
|
- |
|
1427 Records found
|
|
Page 1 of 58 |
|
|
105.06 (14.3%) 
